Atherosclerosis: current pathogenesis and therapeutic options

被引:1708
|
作者
Weber, Christian [1 ,2 ,3 ]
Noels, Heidi [4 ]
机构
[1] Univ Munich, Inst Cardiovas Prevent, Munich, Germany
[2] Munich Heart Alliance, Munich, Germany
[3] Maastricht Univ, Cardiovasc Res Inst Maastricht, Maastricht, Netherlands
[4] Rhein Westfal Tech Hsch Aachen Univ, Inst Mol Cardiovasc Res, Aachen, Germany
基金
欧洲研究理事会;
关键词
LOW-DENSITY-LIPOPROTEIN; CORONARY-ARTERY-DISEASE; ENDOPLASMIC-RETICULUM STRESS; DENDRITIC CELLS; REDUCES ATHEROSCLEROSIS; MYOCARDIAL-INFARCTION; PROMOTES ATHEROSCLEROSIS; MONOCYTE RECRUITMENT; CHEMOKINE RECEPTORS; PLAQUE-FORMATION;
D O I
10.1038/nm.2538
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Coronary artery disease (CAD) arising from atherosclerosis is a leading cause of death and morbidity worldwide. The underlying pathogenesis involves an imbalanced lipid metabolism and a maladaptive immune response entailing a chronic inflammation of the arterial wall. The disturbed equilibrium of lipid accumulation, immune responses and their clearance is shaped by leukocyte trafficking and homeostasis governed by chemokines and their receptors. New pro- and anti-inflammatory pathways linking lipid and inflammation biology have been discovered, and genetic profiling studies have unveiled variations involved in human CAD. The growing understanding of the inflammatory processes and mediators has uncovered an intriguing diversity of targetable mechanisms that can be exploited to complement lipid-lowering therapies. Here we aim to systematically survey recently identified molecular mechanisms, translational developments and clinical strategies for targeting lipid-related inflammation in atherosclerosis and CAD.
引用
收藏
页码:1410 / 1422
页数:13
相关论文
共 50 条
  • [31] Current therapeutic options for gastric adenocarcinoma
    Akshatha, C. R.
    Bhat, Smitha
    Sindhu, R.
    Shashank, Dharini
    Sommano, Sarana Rose
    Tapingkae, Wanaporn
    Cheewangkoon, Ratchadawan
    Prasad, Shashanka K.
    SAUDI JOURNAL OF BIOLOGICAL SCIENCES, 2021, 28 (09) : 5371 - 5378
  • [32] Aggressive lymphomas: Current therapeutic options
    Coiffier, Bertrand
    ANNALS OF ONCOLOGY, 2004, 15 : 11 - 11
  • [33] Current therapeutic options in retinopathy of prematurity
    Krohne, T. U.
    Aisenbrey, S.
    Holz, F. G.
    OPHTHALMOLOGE, 2012, 109 (12): : 1189 - 1195
  • [34] Therapeutic options: Addressing the current dilemma
    Dinan, Timothy
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S119 - S127
  • [35] Pancoast tumour: current therapeutic options
    Palumbo, V. D.
    Fazzotta, S.
    Fatica, F.
    D'Orazio, B.
    Caronia, F. P.
    Cajozzo, M.
    Damiano, G.
    Maffongelli, A.
    Cudia, B. M.
    Messina, M.
    Lo Monte, A. I.
    CLINICA TERAPEUTICA, 2019, 170 (04): : E291 - E294
  • [36] Current therapeutic options in multiple sclerosis
    Tubridy, Niall
    IRISH JOURNAL OF MEDICAL SCIENCE, 2013, 182 : S6 - S6
  • [37] Current therapeutic options for negative symptoms
    Moeller, H. J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S589 - S589
  • [38] Behcet disease: From pathogenesis to novel therapeutic options
    Rodriguez-Carrio, Javier
    Nucera, Valeria
    Masala, Ignazio Francesco
    Atzeni, Fabiola
    PHARMACOLOGICAL RESEARCH, 2021, 167
  • [39] Inflammation in Atherosclerosis: Current Therapeutic Approaches
    Tousoulis, Dimitris
    CURRENT PHARMACEUTICAL DESIGN, 2011, 17 (37) : 4087 - 4088
  • [40] Idiopathic IgA nephropathy: Pathogenesis, histopathology, and therapeutic options
    Tumlin, James A.
    Madaio, Michael P.
    Hennigar, Randolph
    CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2007, 2 (05): : 1054 - 1061